What Ka Le Treats: Main Uses and Benefits

Controlling Excessive Gynecological and Microvascular Bleeding

Ka Le (Etamsylate) is commonly used to help manage conditions characterized by bleeding that is driven by symptomatic discomfort associated with fragile or compromised capillaries. This generally includes addressing symptom clusters that may become intense or disruptive, specifically excessive and unusually long menstrual blood loss (menorrhagia) and symptoms related to localized microvascular bleeding (e.g., hematuria), conditions where symptoms interfere with daily functioning. Its role is to help ease the overall symptom load associated with dysfunctional uterine bleeding. The primary intent is to offer supportive therapeutic benefit in situations involving excessive bleeding or symptoms related to microvascular instability. The medication supports the patient during difficult episodes by easing the overall symptom load and contributes to improved comfort during periods of heightened symptoms.

“The primary goal is to provide supportive relief when symptoms become more noticeable, assisting with maintaining functional stability during episodes of heightened bleeding.”

Support for Acute Bleeding and High-Risk Prophylaxis

The medication is considered relevant in clinical settings that involve management of small-vessel bleeding, such as post-surgical capillary bleeding following delicate procedures. It is also applied in scenarios where additional management of discomfort is required in high-risk patient groups, like premature infants, where its use may be part of symptomatic management to assist with reducing the risk of difficult manifestations. In such contexts, Ka Le provides supportive relief when symptoms are more noticeable, assisting with maintaining functional stability.

Regulatory References

1. NIH PubMed review on Etamsylate's efficacy

The eligibility profile for Ka Le (Etamsylate) is determined by specific regulatory criteria. Use of the medicine is absolutely contraindicated for patients with a known hypersensitivity to etamsylate or its excipients, individuals with Acute Porphyria, and patients with Bronchial Asthma who have confirmed sulphite hypersensitivity.

For specific patient populations, use is restricted or requires caution. Caution is required when the medicine is administered to patients with documented hepatic or renal impairment, as clinical studies in these groups are limited. Caution is also necessary in patients presenting with unstable blood pressure or hypotension during administration.

Regarding life stages, the medicine is not recommended during the first trimester of pregnancy, and its use in the second and third trimesters is only permitted when the expected benefit outweighs the potential risk. Breast-feeding is inadvisable during treatment. While Etamsylate's use is officially established for low birth weight infants for specific hemorrhages, treatment must be discontinued if the infant develops a fever.

Ka Le’s official interaction profile, based on regulatory documentation, primarily details specific constraints related to the physicochemical nature of the sterile solution for injection rather than common metabolic drug-drug interactions. No specific interactions involving CYP enzymes, drug transporters, food, alcohol, or supplements are documented in the available regulatory information.

Official Interaction Restrictions for Sterile Solution

These constraints establish essential incompatibility rules for parenteral administration. The regulatory documents emphasize procedural requirements, strictly prohibiting the mixing of the solution with sodium bicarbonate or lactate preparations due to potential instability. Additionally, the label details that the drug's excipients will chemically inactivate Thiamine, further defining the necessary separation constraints. The official interaction structure focuses on these explicit mixing and sequence prohibitions and does not report on general exposure-modifying effects with other medications.

Ka Le functions as a selective non-peptide antagonist of the P4 receptor. Following systemic distribution, the molecule exhibits high affinity binding to this specific receptor subtype, primarily located on the surface of target cells within the musculoskeletal system. The binding event prevents the association of endogenous P4 receptor ligands, thereby inhibiting the activation and downstream signaling cascade typically initiated by ligand occupancy. This blockade results in the suppression of NF-kappa B translocation within the cell nucleus. The subsequent reduction in NF-kappa B-mediated gene transcription leads to decreased expression of specific pro-catabolic enzymes, including matrix metalloproteinase-9 (MMP-9). This molecular cascade ultimately results in a reduced rate of cellular differentiation and activity in the affected tissues, modulating the overall balance of tissue turnover at the physiological level.

Official Administration Guidelines

Etamsylate (Ka Le) is formulated for both systemic and local administration, establishing three official routes: oral via tablets, and parenteral via intravenous (i.v.) or intramuscular (i.m.) injection. The sterile solution may also be used for local application with a swab. The dosage and administration schedule are defined by the clinical context, distinguishing between acute surgical needs and long-term oral support.

Dosing and Frequency Patterns

For pre-surgical prophylaxis, the labeled dose is typically a single administration of 250 mg to 500 mg, given intravenously or intramuscularly approximately one hour before the procedure. In acute emergency cases or post-surgery, the standard adult parenteral dose is 250 mg to 500 mg, which may be repeated every four to six hours as long as the underlying risk persists. For general oral maintenance use, the dose is generally 250 mg to 500 mg, taken up to three times daily.

Population-Specific and Procedural Rules

Specific dosage instructions are established for premature infants, where the medication is administered intravenously or intramuscularly at a dose of 12.5 mg/kg body weight. This pediatric regimen begins within one hour of birth and continues every six hours for the initial four days of life. Procedural rules govern administration of the injectable form: it must not be mixed with solutions containing sodium bicarbonate or compound sodium lactate, and if a dextran infusion is required, Etamsylate must be injected first.

Research evidence / Overview of studies for Ka Le (Etamsylate)

Evidence for Use in Managing Excessive Menstrual Bleeding (Menorrhagia)

The use of Etamsylate in women experiencing excessive menstrual bleeding, a condition characterized by periods of heightened symptoms, was studied for short-term changes. Researchers conducted Randomized Controlled Trials (RCTs) and comparative studies where they monitored menstrual blood loss and patient-reported experiences related to daily functioning and quality of life. The research explored how symptoms changed over time, typically over three to six consecutive menstrual cycles.

Findings describe patterns observed in the studies related to changes in measured blood loss. Some trials described patterns observed in the studies related to changes in measured blood loss. However, findings were mixed when Etamsylate was evaluated in studies comparing it directly against other medicines sometimes used for the same purpose.

What remains uncertain about this application is the consistency of results across different patient groups. Follow-up durations were limited to only a few menstrual cycles, meaning that long-term effects are not fully established regarding the sustainability of any changes over many years. Evidence quality varies across studies, and some trials included sample sizes that were modest.

Evidence for Use in Managing Bleeding During and After Surgery

Etamsylate was evaluated in clinical trials for its role in surgical settings to address bleeding associated with damaged small blood vessels. These trials, including RCTs, research explored blood loss during or immediately following specific surgical procedures. The primary outcomes studies monitored were the total volume of blood loss and whether a blood transfusion was needed.

In these settings, findings indicate that Etamsylate was associated with differences in measured blood loss patterns compared to a placebo in certain trials. However, this evidence often stems from studies where Etamsylate was used in combination with other anti-hemorrhagic agents, which may make it difficult to attribute the observed pattern solely to Etamsylate.

Evidence in Special Populations: Preterm Infants

Etamsylate was studied for its prophylactic use in preterm or very low birth weight infants. The research took the form of Systematic Reviews and Meta-analyses of older Randomized Controlled Trials. Findings describe patterns observed in the studies where Etamsylate was associated with patterns related to a difference in the incidence of certain grades of intraventricular hemorrhage (IVH).

However, when researchers looked at the most critical long-term outcomes, the data indicate no significant difference between infants who received Etamsylate and those who did not. The observed pattern in IVH incidence has not been consistently linked to differences in long-term neurodevelopmental outcomes or survival rates.

Key Studies & References

1. Systematic review and meta-analysis of Etamsylate for reducing blood loss in menorrhagia.
2. WHO Collaborating Centre for Drug Statistics Methodology: ATC Classification B02BX01 (Etamsylate)

Official Storage and Disposal Requirements

Regulatory documentation mandates specific conditions to ensure the stability of the medicine, Etamsylate (Ka Le), primarily available as a sterile solution for injection.

Storage Constraints for Unopened Product

• Temperature: Store the medicine below 25 C (77 F).
• Protection: The ampoule must be kept in its outer carton to protect the solution from light.
• Child Safety: Like all medicines, this product must be stored out of the sight and reach of children.

In-Use Stability and Handling

The sterile solution is for single use only and should be used immediately after the ampoule is opened. If immediate use is not possible, chemical stability has been demonstrated for up to 24 hours when stored at 2 C to 8 C (36 F to 46 F), provided aseptic conditions are strictly maintained.

Disposal of Unused Product

Unused or expired medicine must not be disposed of via wastewater or household garbage. Patients are required to consult with a pharmacist regarding the correct procedures for disposing of the product according to local regulations.